MEDINET Co., Ltd. AI Stock Analysis
Want to see JP:2370 full AI Analyst Report?
MEDINET Co., Ltd. (2370) AI Stock Analysis
MEDINET Co., Ltd.
(TSE/TYO:2370)
The overall score is heavily pressured by extremely weak technical momentum and a lack of profitability, with the stock in a sustained downtrend and no earnings to support valuation. The primary mitigating factor is the company's exceptionally strong, debt-free balance sheet, which provides financial stability and reduces near-term solvency risk, but this is not enough to offset the fundamental and market-driven headwinds.
MEDINET Co., Ltd. (2370) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 625.71K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 0.69
- Revenue Growth
- 1.41%
- EPS Growth
- 1.12%
- Country
- Japan
- Employees
- 107
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
MEDINET Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnish...
MEDINET Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is a fortress with zero debt, providing a long cash runway. However, the income statement shows deeply negative and widening losses with a -170% net margin, and cash flow is heavily negative, consuming over ¥1.3 billion annually. The company is financially stable in the near term but fundamentally unprofitable.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
22Negative| Breakdown | TTM | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 724.63M | 821.73M | 810.29M | 768.50M | 661.54M | 633.67M |
| Gross Profit | 128.40M | 151.01M | 83.44M | 82.67M | 65.21M | 90.44M |
| EBITDA | -1.29B | -1.42B | -1.26B | -1.20B | -1.36B | -1.17B |
| Net Income | -1.41B | -1.40B | -1.36B | -1.28B | -1.44B | -1.25B |
Balance Sheet | ||||||
| Total Assets | 6.35B | 3.58B | 4.25B | 5.70B | 5.63B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 5.03B | 2.42B | 3.17B | 4.65B | 4.40B | 4.50B |
| Total Debt | 91.32M | 0 | 0 | 781.00K | 2.31M | 4.30M |
| Total Liabilities | 548.63M | 672.01M | 477.10M | 509.95M | 590.60M | 566.58M |
| Stockholders Equity | 5.80B | 2.91B | 3.78B | 5.19B | 5.04B | 5.51B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.35B | -1.44B | -1.25B | -1.28B | -1.14B |
| Operating Cash Flow | 0 | -1.33B | -1.41B | -1.19B | -1.26B | -1.13B |
| Investing Cash Flow | 0 | 553.80M | -565.17M | -12.71M | -2.16M | -50.35M |
| Financing Cash Flow | 0 | 532.79M | -2.55M | 1.46B | 1.16B | 1.58B |
MEDINET Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 16.00 is below the 20-day moving average (MA) of 18.65, below the 50-day MA of 21.74, and below the 200-day MA of 26.16, indicating a bearish trend. The MACD of -1.69 indicates Positive momentum. The RSI at 26.57 is Positive, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.
MEDINET Co., Ltd. Peers Comparison
Overall Rating
JP:238567Neutral
JP:218346Neutral
JP:234244Neutral
JP:237042Neutral
JP:206A37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | JPY 5.41B | 31.17 | ― | 4.83% | -33.44% | 3.65% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | JPY 4.38B | -1.20 | ― | 4.12% | -23.55% | -205.65% | |
| 44Neutral | JPY 3.02B | -156.08 | ― | ― | 8.53% | 97.93% | |
| 42Neutral | JPY 4.55B | -2.95 | ― | ― | 1.41% | 1.12% | |
| 37Underperform | JPY 3.15B | -2.56 | ― | ― | -23.40% | -40.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2370 | MEDINET Co., Ltd. | 16.00 | -17.00 | -51.52% | |
| JP:2183 | Linical Co., Ltd. | 194.00 | -97.98 | -33.56% | |
| JP:2342 | Trans Genic Inc. | 179.00 | -31.00 | -14.76% | |
| JP:2385 | Soiken Holdings Inc. | 207.00 | -12.65 | -5.76% | |
| JP:206A | PRISM BioLab Co. LTD | 85.00 | -84.00 | -49.70% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
